Print
|
Close
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Active:
Yes
Cancer Type:
Lung Cancer
NCT ID:
NCT06211036
Trial Phases:
Phase III
Protocol IDs:
20200041 (primary)
NCI-2024-02774
2023-505989-29
Eligibility:
18 - 99 Years, Male and Female
Study Type:
Treatment
Study Sponsor:
Amgen, Inc.
NCI Full Details:
http://clinicaltrials.gov/show/NCT06211036
Summary
The primary objective of this study is to compare the efficacy of tarlatamab plus
durvalumab with durvalumab alone on prolonging overall survival (OS).
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.